Boehringer Ingelheim GmbH

Employees hang out in the atrium of Building 10, a research and development building, at the Boehringer Ingelheim pharmaceutical campus in Ridgefield, Conn. Monday, April 21, 2014. Members of the Ridgefield Board of Selectmen toured the facility to take note of the recent renovations and see the new ...

Boehringer Ingelheim has expanded access to its digital adherence programme that helps COPD patients take their medicines as prescribed by offering educational and motivational tools. A collaboration with HealthPrize, RespiPoints is a free mobile and web-based programme that's open to patients in ...

The research-driven pharmaceutical company Boehringer Ingelheim can look back on a very successful 2017 financial year. All businesses contributed to net sales growth. R&D expenditure exceeded $3.6 billion, around $3.2 billion of which was in the human pharmaceuticals area alone. In 2017 ...

Family-owned German pharma Boehringer Ingelheim today presented its latest pipeline updates at a R&D press conference titled 'Transcending Disease Boundaries', at its global headquarters in Ingelheim. The company's R&D strategy and current pipeline has the potential to deliver 15 new medicines for ...

Boehringer Ingelheim will partner with Topas Therapeutics to develop virus-based vectors designed to deliver therapeutics, in the initial phase of a broader collaboration aimed at tackling antidrug antibodies (ADAs) by focusing on antigen-specific tolerance induction. Under a multiyear collaboration and ...

The word "gamification" gets tossed around a lot in marketing and loyalty programs, but for Boehringer Ingelheim, it's more than just a buzzword. The pharma recently expanded its RespiPoints online rewards program because it works. After an initial nine-month pilot begun in 2016, Boehringer Ingelheim ...

The German company is paying $37 million in cash and near-term milestones to grab rights to one of the prime targets in the interplay between CD47 and SIRP-alpha. By targeting SIRP-alpha and preventing CD47 from binding to it, investigators at Boehringer believe that they can defuse a key ...

Boehringer Ingelheim Korea said Monday that findings from a study of its chronic obstructive pulmonary disease (COPD) drug Vahelva Respimat showed that it could reduce the risk of exacerbation compared to Spriva Respimat.

A healthcare company that uses artificial intelligence to scan hundreds of NHS stroke patients each year has raised £7m to expand overseas. Brainomix has won the support of the investment arm of German pharma giant Boehringer Ingelheim in a move that will bring its AI technology to hospitals across ...

Boehringer Ingelheim is looking to expand its compound nintedanib to treat some scleroderma patients. And in preparation, it's looking to expand awareness about the disease, too. The company recently rolled out “More Than Scleroderma: The Inside Story,” which features a collection of photos and video ...

Boehringer Ingelheim wants to change that with a global campaign touting the benefits of intervening early on. Called “Why Wait in IPF?” the social media campaign centers on the video story of a grandfather breaking the news about his IPF to his granddaughter. As he explains the incurable lung condition, ...

Trending. Global UV Disinfection Equipment Market 2018 – Getinge Group, STERIS, UltraViolet Devices, Xenex, Lumalier · Home · About Us · Journalists · Contact Us · Home/sci tech/Global Bradykinin B1 Receptor Market 2018 Axxam SpA, Boehringer Ingelheim GmbH, Dompe Farmaceutici S.p.A. ...

Boehringer Ingelheim and Vanderbilt University are expanding their existing collaboration to develop novel anticancer compounds. Boehringer Ingelheim Vanderbilt University anticancer The expanded research partnership will focus on the discovery and development of new chemical therapeutics ...

In part 7 of this Exclusive Interview, Dr. Thomas Seck talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about what's coming up next for Boehringer Ingelheim and Eli Lilly, and knowing the right patient to treat with the newest drugs. Thomas Seck ...

Boehringer Ingelheim and Vanderbilt University today announced the expansion of their successful existing collaboration to develop novel anti-cancer compounds. The expanded research partnership will focus on the discovery and development of new chemical therapeutics targeting the pro-survival ...

(Photos courtesy Boehringer Ingelheim)Vaccines for veterinary patients: Some of 'em go in through a needle; some you squirt up the nose. Then there's intraoral delivery, as in the Recombitek Oral Bordetella vaccine from Merial, now part of Boehringer Ingelheim. The vaccine is administered in a dog's ...

Boehringer Ingelheim and Vanderbilt University will be extending existing collaboration to develop novel anti-cancer compounds. The expanded research partnership will focus on the discovery and development of new chemical therapeutics targeting the pro-survival protein MCL1 as a potential therapy ...

Boehringer Ingelheim and Eli Lilly are expanding their clinical trial programme for Jardiance in chronic heart failure (CHF) with two new Phase III studies. The Emperial clinical trial programme will assess the effect of 12 weeks' treatment with Jardiance (empagliflozin) on exercise ability and heart failure ...

According to Dr. Christa Goodell, DVM, MS, PhD, Dipl ACVPM, technical manager for the Boehringer Ingelheim U.S. Swine Business, “Vaccinating pigs as young as one day old provides protection before pigs are most vulnerable.” Administered intranasally, she said, Ingelvac Provenza provides a direct ...

Even though international guidelines recommend treatment with anti-fibrotic drugs to most IPF patients, a recent European study showed that around 40 percent of patients with a confirmed diagnosis do not receive this type of treatment. Boehringer Ingelheim makes and markets Ofev (nintedanib), one of ...

Negative topline results from two Phase 2 clinical trials have prompted Boehringer Ingelheim to halt further development of its phosphodiesterase E9A inhibitor, BI 409306, for Alzheimer's disease (AD). The compound missed primary cognitive endpoints in both trials of prodromal AD. The company will ...

Boehringer Ingelheim has ditched its Alzheimer's drug after it failed to meet the endpoints of a Phase II trial but will continue to look at it for the treatment of schizophrenia. One of Germany's biggest pharma companies, Boehringer Ingelheim, has given up on the development of its Alzheimer's drug, ...

Following a successful nine-month pilot, Boehringer Ingelheim and HealthPrize Technologies announced that the digital adherence support program RespiPoints will be expanded to any patient who is taking certain Boehringer Ingelheim medications, including some available in the Respimat inhaler.

“Boehringer Ingelheim and Lilly are committed to exploring how Jardiance can improve patient health outcomes and fill treatment gaps to serve as a broad cardiometabolic treatment option,” said Thomas Seck, vice president of clinical development and medical affairs – primary care, at the Ridgefield-based ...

King & Spalding can't arbitrate against Boehringer Ingelheim and its affiliates because of past work the firm did for the companies, a New York trial court ruled Feb. 22. Lawyers who represent clients in an industry with just a few main players should be extra cautious about suing former clients. Any potential ...

March 28, 2018 | March featured exciting new, products, and partnerships from around the bio-IT community from innovating companies, organizations, and universities, including PAREXEL, Vanderbilt University, Boehringer Ingelheim, and more. PAREXEL announced the appointment of Jamie Macdonald as Chief ...

Boehringer Ingelheim is planning to expand its collaboration with Vanderbilt University in the development of anti-cancer drugs. The partnership, announced March 13, will seek to develop new “chemical therapeutics” targeting a protein called MCL1 as a potential therapy against some cancers. This is the ...